of tumour necrosis factor-α (TNF) and perturbations in hormonal homeostasis (Tessitore et al, 1993b) may play an important role in forcing metabolic balance towards the catabolic side.
Interleukin-15 (IL-15) is a novel cytokine first identified in the supernatant of the monkey epithelial cell line CV-1/EBNA as a factor capable of stimulating T-cell activity , and enhancing their antitumour properties (Munger et al, 1995) . Indeed, IL-15 induces T-cell proliferation (Bruton et al, 1994) , enhances natural killer (NK) cell activity, upregulates production of NK-cell-derived cytokines, including γ-interferon (γ-IFN), granulocyte/macrophage-colony stimulating factor (GM-CSF) and TNF (Carson et al, 1994) , and promotes NK cell survival (Carson et al, 1997) . In addition, it stimulates proliferation and differentiation of B cells activated by anti-immunoglobulin M antibodies (Armitage et al, 1995) and may protect T cells and neutrophils from apoptosis (Akbar et al, 1996; Girard et al, 1996) , being a potent inhibitor of apoptosis both in vitro and in vivo (BulfonePaus et al, 1997) . Despite the lack of significant sequence homology, IL-15 shares many biological activities with IL-2 since its function are mediated through the β and γ chains of the IL-2 receptor . However, unlike IL-2, which is produced almost exclusively by activated T cells, the IL-15 gene is not expressed in these cells , but rather IL-15 mRNA has been detected in placenta, skeletal muscle, kidney, lung, heart and intestinal epithelial cells (Reinecker et al, 1996) .
Recently, Quinn et al (1995) Summar y Tissue protein hypercatabolism (TPH) is an important feature in cancer cachexia, particularly with regard to the skeletal muscle. The Yoshida AH-130 rat ascites hepatoma is a model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle wasting, primarily due to TPH. The present study was aimed at investigating if IL-15, which is known to favour muscle fibre hypertrophy, could antagonize the enhanced muscle protein breakdown in this cancer cachexia model. Indeed, IL-15 treatment partly inhibited skeletal muscle wasting in AH-130-bearing rats by decreasing (8-fold) protein degradative rates (as measured by 14 C-bicarbonate pre-loading of muscle proteins) to values even lower than those observed in non-tumourbearing animals. These alterations in protein breakdown rates were associated with an inhibition of the ATP-ubiquitin-dependent proteolytic pathway (35% and 41% for 2.4 and 1.2 kb ubiquitin mRNA, and 57% for the C8 proteasome subunit, respectively). The cytokine did not modify the plasma levels of corticosterone and insulin in the tumour hosts. The present data give new insights into the mechanisms by which IL-15 exerts its preventive effect on muscle protein wasting and seem to warrant the implementation of experimental protocols involving the use of the cytokine in the treatment of pathological states characterized by TPH, particularly in skeletal muscle, such as in the present model of cancer cachexia. © 2000 Cancer Research Campaign
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: IL-15; cancer cachexia; protein turnover; skeletal muscle; proteasome; ubiquitin contractile proteins (Quinn et al, 1995) , suggesting that IL-15 may play a role in skeletal muscle fibre growth in vivo. Bearing all this in mind, it was the aim of the present investigation to assess the effects of IL-15 administration on the skeletal muscle protein turnover in rats bearing a cachexia-generating, fast-growing tumour.
MATERIALS AND METHODS

Animals, tumour inoculation and treatment
Male Wistar rats (Interfauna, Barcelona, Spain) weighing approximately 110-135 g were utilized. The animals were maintained on a regular light-dark cycle (light from 8 am to 8 pm) and had free access to food and water. The diet (Panlab, Barcelona, Spain) consisted of 54% carbohydrate, 17% protein and 5% fat (the residue was non-digestible material). Rats were divided into two groups, controls and tumour hosts. The latter received an intraperitoneal inoculum of 10 8 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumours (for details see Tessitore et al, 1987a) . Both groups were further divided into treated and untreated, the former being administered a daily s.c. dose of IL-15 (100 µg kg -1 b.w. dissolved in physiological saline solution), the latter a corresponding volume of vehicle.
On days 0, 4, and 7 after tumour transplantation, animals were weighed and anaesthesized with diethyl ether. The tumour was harvested from the peritoneal cavity, its volume and cellularity evaluated. Blood was collected from the abdominal aorta into heparinized tubes and centrifuged (3500 g, 10 min, 4°C) to obtain plasma. Tissues were rapidly excised, weighed, and frozen in liquid nitrogen (Tessitore et al, 1987a; .
Protein turnover
Protein turnover rates were determined by a method that, as previously discussed (Tessitore et al, 1987a (Tessitore et al, , 1993a , offers the best compromise for monitoring protein synthesis and degradation simultaneously in the same animal (Garlick et al, 1975) . Briefly, apparent rates of synthesis and degradation for proteins of the slow turnover pool were evaluated by measuring the decay in specific and total protein radioactivity in tibialis muscles after labeling in vivo, 24 h before tumour transplantation, with a single intraperitoneal dose of sodium 14 C-bicarbonate (250 µCi kg -1 b.w.). Four days after tumour inoculation, fractional rates of protein degradation (k d ), synthesis (k s ), and accumulation (k a ) were calculated as follows and expressed as % per day: k d = ln(total protein radioactivity)/t k s = ln(specific protein radioactivity)/t k a = ln(total protein)/t Muscle protein extraction was carried out by using a trichloroacetic acid precipitation method, as previously described (Costelli et al, 1993) . Tissue protein was determined by the method of Bradford (1976) , using bovine serum albumin as working standard.
RNA isolation and Northern blot analysis
Total RNA from tibialis muscle was extracted using the acid guanidinium isothiocyanate/phenol/chloroform method as described by Chomczynski and Sacchi (1987) . RNA samples (20 µg) were denatured, subjected to 1.2% agarose gel electrophoresis and transferred to Hybond N membrane (Amersham). RNA was fixed to the membranes by Genelinker (Biorad).
The RNA in gel and filters was visualized with ethidium bromide and photographed by UV transillumination to ensure the integrity of RNA, to check the loading of equivalent amounts of RNA and to confirm proper transfer. RNA was trasferred in 20 × standard saline citrate (SSC: 0.15 M NaCl and 15 mM sodium citrate, pH 7.0). Hybridization was done at 65°C overnight in the hybridization buffer (0.25 M Na 2 HPO 4 , 7% SDS, 1 mM EDTA, 1% BSA, 10% dextran sulphate), and denatured labelled probes (10 6 -10 7 cpm ml -1 ) were added. Radiolabelled probes were prepared by the random priming method (Boehringer-Mannheim). The ubiquitin probe used was a cDNA clone containing 12 base pairs of the second ubiquitin coding sequence plus a complete third and fourth ubiquitin coding sequence and 120 base pairs of the 3′-untranslated region of the chicken polyubiquitin gene UB1 (Bond and Schlesinger, 1985) . The C8 proteasome subunit probe used was a cDNA clone containing 850 base pairs of the rat C8 proteasome gene (Tanaka et al, 1990) . UV light-illuminated ethidium bromide staining of the 28S rRNA was used as a control of loading. Filters were exposed to Hyperfilm-MP films (Amersham) at -80°C for 2-4 days and quantified by scanning densitometry.
Plasma hormones
Circulating corticosterone was evaluated by a rat radioimmunoassay (IDS, Boldon, England). Insulin was measured by radioimmunoassay by the method of Albano et al (1972) , using rat insulin as working standard.
Data presentation
Data are given as means ± SEM Student's t-test was used to calculate the significance of differences.
Chemicals
All enzymes and coenzymes were obtained from BoehringerMannheim (Barcelona, Spain) or Sigma (St. Louis, MO, USA), sodium 14 C-bicarbonate (53 mCi mmol -1 ) from New England Nuclear (Boston, MA, USA). Recombinant human IL-15 was kindly provided by Immunex Corporation (Seattle, Washington, USA).
RESULTS
The Yoshida AH-130 rat ascites hepatoma grew exponentially for 4-5 days then shifted into a stationary phase approximately 7 days after transplantation, as previously shown (Tessitore et al, 1987b) . Tumour growth was not significantly affected by IL-15 (Table 1) .
As shown in Table 1 , the loss of body weight in tumour bearers became clear by day 7 and was less marked in the IL-15-treated tumour-bearing group. A reduction of white adipose tissue mass was detectable at day 4 in IL-15-treated controls; this tissue was also diminished in tumour bearers (both at days 4 and 7), yet not further affected to a significant degree by the cytokine treatment. Liver was hypotrophic 4 days after tumour inoculation and even more so by day 7, when a significant protective effect exerted by IL-15 on this tissue was observed.
Quite different was the pattern with regard to skeletal muscle. A decrease in wet weight (Table 2 ) and protein content (Table 3) was elicited by tumour growth, as previously reported (Tessitore et al, 1987a) . Treatment with IL-15 partially prevented the protein waste in tibialis muscle (Table 3 ). This protective effect was also noticeable in terms of wet tissue weight for the skeletal muscles (Table 2 ). In agreement with previous observations (Carbó et al, 2000) , IL-15 did not exert any trophic action (weight or protein increase) on muscles in non-tumour bearers (Tables 2 and 3) .
Protein turnover in tibialis muscle 4 days after tumour inoculation was evaluated to determine if the protein-sparing action of IL-15 was exerted by changes in muscle protein degradation or synthesis, or both (Table 4) . As previously reported (Tessitore et al, 1987a (Tessitore et al, , 1993a , rates of tibialis muscle protein degradation were enhanced (48%) as a consequence of tumour growth, while muscle protein synthesis remained virtually unchanged, resulting in protein accumulation rates lower (27%) than in controls (Table 4) . On treatment with IL-15, the elevation of protein breakdown rates was suppressed and protein accumulation rates returned to levels similar to those in controls (Table 4) . No detectable effect was observed with regard to protein synthesis rates. In non-tumour bearers, IL-15 treatment resulted in a decrease in protein degradation Data are expressed as means ± SEM. Tissue weights are expressed as mg per 100 g of initial body weight. Final body weight excludes tumour weight. Significance of the differences (Student's t-test): a = P < 0.05, b = P < 0.01, c = P < 0.001 (vs non-tumour bearers); d = P < 0.05, e = P < 0.01 (vs. non-treated). n = 4 and 6 for non-tumour and tumour bearers, respectively. WAT = white adipose tissue; BAT = brown adipose tissue Data are expressed as mean ± SEM. Statistical comparison of the data (Student's t-test): a = P < 0.05, b = P < 0.001 (vs non-tumour bearers); c = P < 0.05 (vs non-treated). n = 4 and 6 for non-tumour and tumour bearers respectively. ibw = initial body weight.
(70%) and synthesis (12%) rates, which resulted in no changes in protein accumulation (Table 4) . As previously shown (Llovera et al, 1994) , the accelerated muscle protein breakdown in the AH-130 hosts is associated with activation of the ATP-ubiquitin-dependent proteolytic system. Two polyubiquitin mRNA species (2.4 kb and 1.2 kb) were found in tibialis muscle (Figure 1 ). 7-day tumour-bearing animals showed an increased expression of the polyubiquitin genes compared with the corresponding control animals: over 3-fold for both ubiquitin transcripts. The expression of the C8 proteasome subunit was also increased as a result of tumour burden (Figure 1 ). Control animals receiving IL-15 also showed significant decreases in the expression of these genes, in agreement with the decreased protein degradation associated with IL-15 treatment (Table 4 ). In addition, when the tumour-bearing animals received IL-15, the activation of this proteolytic system was also suppressed ( Figure  1) .
Corticosterone was elevated (day 7) and insulin decreased (days 4 and 7) in the blood plasma of AH-130 hosts at day 7, as previously observed (Tessitore et al, 1993b) . When these animals were administered IL-15, neither insulin nor corticosterone levels were significantly affected, suggesting that the effects of the cytokine were not mediated through these hormones. In non-tumour bearers, the treatment did not modify insulin concentrations (Table  5) .
DISCUSSION
Muscle protein wasting is a prominent feature in cancer cachexia and is primarily ascribed to enhanced tissue protein catabolism (Kien and Camitta, 1983; Beck and Tisdale, 1989; Melville et al, 1990; Beck et al, 1991; Tessitore et al, 1993a) . Most therapeutic approaches to cancer cachexia have been designed on the assumption that tissue wasting merely results from undernutrition or tumour-host competition, yet parenteral nutrition or overfeeding have proven to be only marginally or, at best, temporarily effective (Moley et al, 1988; Popp et al, 1988; Shaw and Wolfe, 1988) . Moreover, in some cases the tumour itself apparently took more advantage of such a treatment than the patient (Tayek et al, 1986; Popp et al, 1988) .
The rat tumour model used in the present study quickly causes progressive body weight loss and tissue protein wasting. The latter is associated with tissue protein hypercatabolism (TPH) (Tessitore et al, 1987a; 1987b; which is probably mediated by production of cytokines such as TNF (García-Martínez et al, 1993; Llovera et al, 1993a Llovera et al, , 1993b and alterations in hormonal homeostasis (Tessitore et al, 1993a) . The beneficial effects of treatments with anti-TNF antibodies (Costelli et al, 1993) or with drugs interfering with the development of TPH have been previously reported. The present observations show that treatment of the AH-130 hosts with IL-15 inhibits some of the protein loss in the tibialis muscle by reverting the increase in protein degradation. This is consistent with previous reports indicating that IL-15 may act as an anabolic cytokine for skeletal muscle (Quinn et al, 1995) . IL-15 activates NK cells (Carson et al, 1994; , which have anti-tumour properties; however, it has to be pointed out that IL-15 had no effect on tumour growth in our model. Thus, the effects of IL-15 on tumour-induced wasting could not be related to the anti-tumour action of this cytokine.
The precise mechanisms by which intracellular proteins are degraded are largely unknown, although it is accepted that proteolysis may occur inside and outside the lysosomes. Lysosomal proteases, in particular cathepsins, are not the major mediators of myofibrillar protein degradation in rat skeletal muscle (Lowell et al, 1986; Tessitore et al, 1994) . The ATP-ubiquitin-dependent proteolytic system is postulated to account for the turnover of short-lived proteins (Ciechanover et al, 1984) or for abnormal proteins formed during stress such as heat-shock (Bond et al, 1988) . However, it has been suggested that the activity of this Expression of ubiquitin and C8 proteasome subunit mRNAs in tibialis muscles from control (C), control treated with IL-15 (IL-15), 7-day tumourbearing (T) and 7-day tumour-bearing treated with IL-15 (T+IL-15). mRNA was detected after hybridization with a cDNA probe containing a region of the chicken polyubiquitin gene UB1 or the C8 gene. Autoradiographs were subjected to scanning densitometry. Ethidium bromide (EtBr) was used for total RNA quantitation in order to correct the results system can also be related to the turnover of long-lived proteins such as those found in skeletal muscle (Hilenski et al, 1992) . Recently, this proteolytic system has been involved in the perturbations of protein metabolism in skeletal muscle in many pathological conditions (see Argilés and López-Soriano, 1996 for review). Previous studies from our laboratory have shown that the lysosomal pathway is only marginally involved in the development of muscle protein hypercatabolism in the AH-130 hosts (Llovera et al, 1994; Tessitore et al, 1994) , while an important activation of the ATP-dependent proteolysis seems to be the major mechanism (Llovera et al, 1994; Costelli et al, 1995) . It is very interesting to observe that the preventive effect exerted by IL-15 on the acceleration of muscle protein breakdown is associated with a normalization of the hyperexpression of both the C8 proteasome subunit and the ubiquitin mRNAs. Moreover, the present observation that IL-15 administration to control rats reduces ubiquitin and C8 mRNAs expression below the basal values should be stressed. To the best of our knowledge, this is the first report showing that the effect of IL-15 on muscle protein turnover may be due to downregulation of the ATP-ubiquitin-dependent proteolytic system. The action of the cytokine on muscle protein metabolism in skeletal muscle might involve hormonal modulations. However, as far as insulin and corticosterone are concerned, the present study suggests that this is not the case for the AH-130 hosts, since the altered plasma level of neither hormone was corrected by the treatment.
Another important action of IL-15 is to reduce the body fat content by inhibiting lipogenesis (Carbó et al, 2000) ; tissuespecific modulations in lipoprotein lipase activity could provide an additional mechanism for promoting a decreased lipid accretion in adipose tissue. The present cachexia model is itself characterized by extensive lipid mobilization (Dessì et al, 1992; Carbó et al, 1994) , associated with decreased activity of tissue lipoprotein lipase (Carbó et al, 1994) . The lack of effect of IL-15 on adipose tissue in AH-130 hosts may thus reflect the fact that lipid mobilization was already occurring in these animals and could not easily be stimulated further. When the cytokine treatment was applied to control rats, however, adipose tissue mass decreased with respect to untreated controls (by 34%), in agreement with previous reports (Carbó et al, 2000) .
In conclusion, the present results indicate that IL-15 exerted a selective, protective action on skeletal muscle by antagonizing both the enhanced protein degradation and, to some extent the resulting protein loss, which characterize cachexia in AH-130 tumour-bearing rats. These observations suggest that the cytokine could be a convenient therapeutic tool in pathological states where muscle protein hypercatabolism is a critical feature, such as cancer cachexia or other wasting diseases. Data are means ± S.E.M. Significance of the differences (Student's t test): a = P < 0.05, b = P < 0.001 (vs control days 4-7); c = P < 0.05 (vs nontreated). n = 4 and 6 for non-tumour and tumour bearers respectively
